LULU Dec 2023 300.000 call
| Previous close | 145.60 |
| Open | 145.60 |
| Bid | 164.95 |
| Ask | 169.15 |
| Strike | 300.00 |
| Expiry date | 2023-12-15 |
| Day's range | 145.60 - 145.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 51 |
ZacksImproved Traffic to Drive lululemon's (LULU) Q3 Earnings Beat
lululemon (LULU) Q3 results are expected to benefit from improved store and online traffic. The company is also likely to have gained from lower air freight expenses, which is likely to have boosted the gross margin.
- Yahoo Finance Video
Weight loss drugs likely to boost apparel stocks: Survey
The market for GLP-1 weight loss drugs such as Wegovy and Ozempic have captured Wall Street's attention. A consumer survey carried out by Stifel Financial (SF) found 15% of respondents currently use a GLP-1 drug while an additional 21% said they would be interested if it were FDA approved with proven results. Stifel Analyst Jim Duffy joins Yahoo Finance to discuss how the uptake of weight loss drugs could prompt a shift in spending trends and the greater impact of GLP-1's across industries. "We do expect that there will be less calories consumed, by the projections of our food & beverage team, get to 4% less calories consumed with this adoption. We do think that there's going to be more apparel spend," Duffy says. "Consumers are losing significant amounts of weight on these drugs, some clinical trials, including one released recently from Mounjaro, speaks to greater than 40% of consumers losing more than 10% of their body weight." Duffy names Lululemon (LULU), Dick's Sporting Goods (DKS) and Levi's (LEVI) as potential winners. Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here.
ZacksLululemon (LULU) Reports Next Week: Wall Street Expects Earnings Growth
Lululemon (LULU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
